AI assistant
Saniona Share Issue/Capital Change 2024
3195_rns_2024-10-31_6241b14b-3f3e-4b3b-a77c-8e01528fb062.pdf
Share Issue/Capital Change
Open in viewerOpens in your device viewer
PRESS RELEASE
31 October 2024 11:30:00 CET
Change in number of shares and votes in Saniona AB
During the month of October, the registered number of shares and votes in Saniona AB ("Saniona") has increased due to conversion of the outstanding convertibles issued by Saniona to Fenja Capital II A/S on 15 February 2024. As of 31 October 2024, the registered number of shares and votes in Saniona amounts to 111,885,501.
For more information, please contact
Thomas Feldthus, CEO, +45 22109957; [email protected]
About Saniona
Saniona (OMX: SANION) is a clinical-stage biopharmaceutical company leading the way in ion channel modulation for the treatment of epilepsy and other neurological disorders. Saniona's epilepsy pipeline features SAN711, a Phase 2-ready candidate drug targeting absence seizures, SAN2219 for acute repetitive seizures, and SAN2355, addressing refractory focal onset seizures. Beyond epilepsy, Saniona oversees four clinical programs poised for collaboration. Tesofensine, Saniona's most advanced candidate, is progressing towards regulatory approval for obesity in Mexico through a partnership with Medix. Tesomet™ is ready for Phase 2b, targeting rare eating disorders, while SAN903 is ready for Phase 1 for inflammatory bowel disease and SAN2465 is set for preclinical development for major depressive disorder. Saniona has esteemed partners, including Boehringer Ingelheim GmbH, Productos Medix, S.A de S.V, AstronauTx Limited, and Cephagenix ApS. Saniona is based in Copenhagen and listed on Nasdaq Stockholm Main Market. For more information, please visit www.saniona.com.
This information is information that Saniona AB (publ) is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2024-10-31 11:30 CET.
Email: [email protected]
Web: saniona.com